Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Indivior Pharmaceuticals (INDV) EBT Margin (2022 - 2025)

Historic EBT Margin for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to 11.78%.

  • Indivior Pharmaceuticals' EBT Margin rose 20100.0% to 11.78% in Q3 2025 from the same period last year, while for Sep 2025 it was 16.61%, marking a year-over-year increase of 129800.0%. This contributed to the annual value of 1.68% for FY2024, which is 149500.0% up from last year.
  • Latest data reveals that Indivior Pharmaceuticals reported EBT Margin of 11.78% as of Q3 2025, which was up 20100.0% from 20.53% recorded in Q2 2025.
  • Over the past 5 years, Indivior Pharmaceuticals' EBT Margin peaked at 26.24% during Q2 2022, and registered a low of 106.22% during Q4 2022.
  • Its 4-year average for EBT Margin is 0.35%, with a median of 20.67% in 2023.
  • Data for Indivior Pharmaceuticals' EBT Margin shows a peak YoY increase of 1270400bps (in 2023) and a maximum YoY decrease of -900700bps (in 2023) over the last 5 years.
  • Quarter analysis of 4 years shows Indivior Pharmaceuticals' EBT Margin stood at 106.22% in 2022, then soared by 120bps to 20.82% in 2023, then tumbled by -39bps to 12.75% in 2024, then dropped by -8bps to 11.78% in 2025.
  • Its EBT Margin was 11.78% in Q3 2025, compared to 20.53% in Q2 2025 and 22.18% in Q1 2025.